Health Affairs, 27, no. 4 (2008): w310-w314 (Published online 17 June 2008) doi: 10.1377/hlthaff.27.4.w310 © 2008 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Culliton, B. J. Search for Related Content PubMed PubMed Citation Articles by Culliton, B. J. Related Collections Legal/Regulatory Issues Pharmaceuticals Research And Technology Related Article

Web Exclusives

INTERVIEW

Nanomedicine—The Power Of Proteins: A Conversation With Lance Liotta And Emanual Petricoin

Molecularly targeted cancer drugs have begun to usher in the promise of personalized medicine, where genetic tests determine whether a therapy is prescribed. Because these new drugs are costly, many insurers require gene tests as a precondition of payment. But there is still an element of doubt, because the drugs act on proteins, not genes. More accurate ways to match patients and therapies may come from proteomics, where scientists are developing methods for identifying the proteins that are active in diseased tissues. In this interview, Barbara Culliton discusses the promise of proteomics with Lance Liotta and Emanual Petricoin, two scientists operating at the frontiers of that field.

                      What's this?

Related Article

• Barbara J. Culliton
  Is Special FDA Regulation Of Nanomedicine Needed? A Conversation With Norris E. Alderson
  Health Affairs, July/August 2008; 27(4): w315-w317.
  [Abstract] [Full Text] [PDF]